4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Avalo Therapeutics, Inc. (AVTX) operates in the Biotechnology industry and is headquartered in Wayne, United States with about 33 employees. Its market capitalization is roughly $976 million. In the fiscal year ended 2025-12-31, AVTX reported $0M in revenue and ($78M) in net income.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States.
Interactive charts & full statements → Open the AVTX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $2M | $18M | — |
| Gross Profit | $0M | $1M | $1M | $15M | — |
| Operating Income (EBIT) | ($73M) | ($41M) | ($23M) | ($37M) | — |
| Net Income | ($78M) | ($35M) | ($32M) | ($42M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($21M) | ($20M) | ($19M) | ($19M) | ($15M) | — |
| Net Income | ($20M) | ($14M) | ($31M) | ($21M) | ($13M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $116M | $151M | $21M | $33M | — |
| Total Liabilities | $33M | $18M | $14M | $44M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AVTX viewer.
About TickerBase · Data methodology & sources